ArticleJournal of inflammation research2025
Exploring the Anti-Inflammatory and Anti-NET Properties of Zidian Zhenxiao Granule in IgA Vasculitis: A Network Pharmacology and Proteomic Study.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut microbiota in Henoch-Schönlein purpura: from pathogenesis to therapeutic strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Purpose: Immunoglobulin A vasculitis (IgAV) is the most common systemic vasculitis of childhood. Zidian Zhenxiao granule (ZDZX), a 9-herb formula optimized through decades of clinical practice, uniquely integrates anti-inflammatory and immunomodulatory properties. However, its mechanisms targeting neutrophil extracellular traps (NETs) and thromboinflammatory pathways in combating IgAV remain unclear. This study aimed to investigate the main component of ZDZX and its underlying mechanism in IgAV treatment. Methods: Combining UHPLC-QE-MS/MS, network pharmacology, 4D-FastDIA proteomics, and a gliadin-induced IgAV murine model, we systematically deciphered ZDZX's renoprotective and anti-inflammatory mechanisms. Results: 19 key components were identified in ZDZX, targeting 46 IgAV-associated proteins, predominantly enriched in TNF and IL-17 signaling pathways. In vivo, ZDZX significantly reduced levels of blood urea nitrogen (BUN) and creatinine ( Conclusion: By synergizing network pharmacology, 4D-FastDIA proteomics, and experimental validation, this study pioneers the demonstration that ZDZX alleviates IgAV via multi-target inhibition of NET-driven thromboinflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.